<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005102A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005102</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13933019</doc-number><date>20130701</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>9</main-group><subgroup>12</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>9</main-group><subgroup>1241</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>514  38</main-classification><further-classification>530350</further-classification><further-classification>536 231</further-classification><further-classification>514  37</further-classification><further-classification>514  42</further-classification><further-classification>514  43</further-classification></classification-national><invention-title id="d0e43">Oligoadenylate Synthetase (OAS)</invention-title><us-related-documents><division><relation><parent-doc><document-id><country>US</country><doc-number>13364140</doc-number><date>20120201</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>8486678</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13933019</doc-number></document-id></child-doc></relation></division><continuation><relation><parent-doc><document-id><country>US</country><doc-number>12750545</doc-number><date>20100330</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>8133710</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13364140</doc-number></document-id></child-doc></relation></continuation><division><relation><parent-doc><document-id><country>US</country><doc-number>11601440</doc-number><date>20061117</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>7732177</doc-number></document-id></parent-grant-document></parent-doc><child-doc><document-id><country>US</country><doc-number>12750545</doc-number></document-id></child-doc></relation></division><us-provisional-application><document-id><country>US</country><doc-number>60752668</doc-number><date>20051221</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>60739159</doc-number><date>20051123</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Kineta Two LLC</orgname><address><city>Seattle</city><state>WA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Iadonato</last-name><first-name>Shawn P.</first-name><address><city>Seattle</city><state>WA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Magness</last-name><first-name>Charles L.</first-name><address><city>Seattle</city><state>WA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Branum</last-name><first-name>Mark</first-name><address><city>Bellevue</city><state>WA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>McVean</last-name><first-name>Maralee</first-name><address><city>Seattle</city><state>WA</state><country>US</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>Scherer</last-name><first-name>Christina</first-name><address><city>Seattle</city><state>WA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Kineta Two LLC</orgname><role>02</role><address><city>Seattle</city><state>WA</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.</p></abstract></us-patent-application>